Search
Anika Therapeutics Inc
ANIKAdd to Watchlist
14.620USD
-0.110-0.75%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
194.53MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.75%
5 Days
+1.39%
1 Month
-1.75%
6 Months
+54.22%
Year to Date
+52.13%
1 Year
+31.47%
Key Figures
14.730Open
14.900High
43.06KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.32%Turnover Ratio
14.730Prev. Close
14.590Low
469.58KTurnover
LossP/E Static
1.46P/B
0.00%Div Yield TTM
-5.99%ROA
16.24052wk High
0.49Volume Ratio
-56.38MNet Profit
13.36MShares
-0.7916EPS TTM
0.22Beta
-7.85%ROE
7.87052wk Low
2.10%Amplitude
64.15%Gross Margin
194.53MMarket Cap
-0.17Reward/Risk
3.27%Risk Rate
TradingKey Stock Score of Anika Therapeutics Inc
Currency: USD Updated: 2026-06-25Key Insights
Anika Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 203 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 17.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Anika Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Anika Therapeutics Inc Highlights
StrengthsRisks
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Undervalued
The company’s latest PE is -18.47, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.85M shares, decreasing 11.14% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 28.62K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.31.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
17.500
Target Price
+19.95%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Anika Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Anika Therapeutics Inc Info
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Ticker SymbolANIK
CompanyAnika Therapeutics Inc
CEOBlanchard (Cheryl Renee)
Websitehttps://anika.com/
Related Instruments
+2.48%
+2.79%
+3.08%
-0.53%
+2.39%
+2.80%
+0.84%
+0.51%
-0.20%
+0.93%
+0.93%
-0.57%
+0.87%
+0.11%
+4.77%
+3.92%
+1.05%
+2.49%
+2.97%
+0.30%Popular Instruments
51887.400
-137.300 (-0.26%)
29085.300
-369.700 (-1.25%)
7320.700
-46.100 (-0.63%)
15162.000
-589.000 (-3.74%)
69112.000
-2020.000 (-2.84%)
6222.400
-43.400 (-0.69%)
69.348
-1.996 (-2.80%)
275.150
-17.930 (-6.12%)
195.740
-3.260 (-1.64%)
4038.900
+12.750 (+0.32%)
FAQs
What is the current price of Anika Therapeutics Inc (ANIK)?
The current price of Anika Therapeutics Inc (ANIK) is 14.62.
What is the symbol of Anika Therapeutics Inc?
The ticker symbol of Anika Therapeutics Inc is ANIK.
What is the 52-week high of Anika Therapeutics Inc?
The 52-week high of Anika Therapeutics Inc is 16.24.
What is the 52-week low of Anika Therapeutics Inc?
The 52-week low of Anika Therapeutics Inc is 7.87.
What is the market capitalization of Anika Therapeutics Inc?
The market capitalization of Anika Therapeutics Inc is 195.28M.
Is Anika Therapeutics Inc (ANIK) currently rated as Buy, Hold, or Sell?
According to analysts, Anika Therapeutics Inc (ANIK) has an overall rating of STRONG BUY, with a price target of 17.50.
What is the Earnings Per Share (EPS TTM) of Anika Therapeutics Inc (ANIK)?
The Earnings Per Share (EPS TTM) of Anika Therapeutics Inc (ANIK) is -0.76.
